GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baxalta Inc (NYSE:BXLT) » Definitions » Tangible Book per Share

Baxalta (Baxalta) Tangible Book per Share : $2.95 (As of Mar. 2016)


View and export this data going back to 2015. Start your Free Trial

What is Baxalta Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Baxalta's tangible book value per share for the quarter that ended in Mar. 2016 was $2.95.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Baxalta Tangible Book per Share Historical Data

The historical data trend for Baxalta's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxalta Tangible Book per Share Chart

Baxalta Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Tangible Book per Share
- - - 2.65

Baxalta Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 7.59 3.67 2.66 2.65 2.95

Competitive Comparison of Baxalta's Tangible Book per Share

For the Biotechnology subindustry, Baxalta's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baxalta's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Baxalta's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Baxalta's Price-to-Tangible-Book falls into.



Baxalta Tangible Book per Share Calculation

Baxalta's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2015 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(3924-0-2124)/679.287
=2.65

Baxalta's Tangible Book Value Per Share for the quarter that ended in Mar. 2016 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(4220-0-2203)/682.775
=2.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Baxalta  (NYSE:BXLT) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Baxalta Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Baxalta's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Baxalta (Baxalta) Business Description

Traded in Other Exchanges
N/A
Address
Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.
Executives
Gail D Fosler director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
John Glasspool officer: See Remarks C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Dagmar Rosa-bjorkeson officer: EVP and President, Biosimilars C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
David D. Meek officer: EVP and President, Oncology 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Karen Jean Ferrante director 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Peter G Edwards officer: SVP and General Counsel C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Robert J. Hombach officer: EVP. CFO and COO C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Blake E Devitt director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Wayne T Hockmeyer director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anne-marie Law officer: EVP & Head of Human Resources C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Stroucken Albert P L director BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Gavin James R Iii director BAXTER INTERNATIONAL INC, ONE BAXTER PARKWAY, DEERFIELD IL 60015
John D Forsyth director C/O BAXTER INTERNATIONAL, ONE BAXTER PARKWAY, DEERFIELD IL 60015
Ludwig Hantson director, officer: President and CEO C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921

Baxalta (Baxalta) Headlines

From GuruFocus

Keeley Funds Comments on Baxalta Inc.

By Holly LaFon Holly LaFon 02-03-2016

Daniel Loeb Comments on Seven & i Holdings

By Holly LaFon 11-03-2015

Baxalta: A Rare Undervalued Biopharmaceutical Company

By Ben Reynolds Ben Reynolds 07-23-2015

Jeff Auxier Sells Precision Castparts, AT&T, Microsoft

By Tiziano Frateschi Tiziano Frateschi 06-23-2016

Baxalta Vs. AbbVie: Biopharma Spin-Off Battle

By Ben Reynolds Ben Reynolds 08-20-2015

Tweedy Browne Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 01-27-2016

Third Avenue Buys Baxter Spin-Off

By Kyle Ferguson Kyle Ferguson 01-17-2016

Third Avenue Management Comments on Baxalta

By Holly LaFon Holly LaFon 12-10-2015

Is Baxalta a Good Spin-Off Opportunity?

By Raman Minhas Raman Minhas 10-15-2015